Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow declines year over year

Q1 FY2026 investing cash flow of $10.32M fell 20.6% year over year, ahead of the -246.4% change in trailing-twelve-month investing cash flow. Over 3 fiscal years it compounded at -25.1% a year.

Context

  • Investing cash flow amounted to 80.5% of revenue in FY2025, down 415.7 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -20.6% holds above the trailing-twelve-month pace of -246.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.32M+158.3% QoQ
Last fiscal yearDec 2025
-$26.94M-305.8% YoY
LTMMar 2026
-$29.62M-246.4% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.6%——
1 year-305.8%——
3-year CAGR-25.1%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(26.94M) USD
Year-over-year change
-305.8%

Investing Cash Flow vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -246.4% is the 9th highest of 10, against a peer median of +20.9%.
  • Investing cash flow amounts to 90.5% of revenue for OBIO, versus a peer median of 557.3%.
OBIO Competitors
Investing Cash Flow for OBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€127.93M EUR-1562.9%—2853.7%
TARAProtara Therapeutics, Inc.LTM Mar 2026$95.86M USD+53.9%——
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$79.35M USD+34244.9%——
CRBUCaribou Biosciences, Inc.LTM Mar 2026$76.84M USD-32.0%—685.9%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$59.54M USD-177.1%-9.8%86.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$59.41M USD+39.9%—428.7%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$56.22M USD—+851.0%95279.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$33.77M USD+20.9%-12.5%15008.9%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$29.62M USD-246.4%-25.1%90.5%
IVVDInvivyd, Inc.LTM Mar 2026$737K USD+411.8%-91.2%1.3%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$228K USD-100.2%-13.2%1.4%
Peer median (excluding OBIO) —+20.9%-12.5%557.3%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Depreciation & Amortization181K222K287K308K327K
Deferred Income Tax288K0000
Stock-Based Compensation302K3.41M7.63M10.62M11.98M
Change in Working Capital2.6M(451K)(3.31M)(765K)(10.37M)
Accounts Receivables47K25K(3K)22K(3K)
Inventory1K(208K)131K(28K)(137K)
Accounts Payables1.08M0145K2.97M0
Other Working Capital1.47M(268K)(3.58M)(3.73M)(10.23M)
Other Non-Cash Items217K1.14M(1.61M)308K1.81M
Operating Cash Flow(19.43M)(29.29M)(46.13M)(50.56M)(48.96M)
Capital Expenditures(274K)(591K)(78K)(289K)(489K)
Acquisitions (Net)(13.29M)00(602K)0
Purchases of Investments(213K)(63.53M)(142.03M)(72.65M)(76.31M)
Sales of Investments13.5M0152.8M86.63M49.86M
Other Investing Activities13.29M0000
Investing Cash Flow13.02M(64.12M)10.69M13.09M(26.94M)
Debt Repayment(4M)3.55M(10.85M)15M17.91M
Common Stock Issued7K109.83M254K15.04M71.97M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7K(10.13M)56.81M(864K)(1.55M)
Financing Cash Flow(3.99M)103.26M46.22M29.17M88.33M
Effect of Forex Changes00000
Net Change in Cash(10.41M)9.85M10.78M(8.3M)12.43M
Free Cash Flow(19.7M)(29.88M)(46.21M)(50.85M)(49.45M)

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.